Acquisitions In Brief
This article was originally published in The Gray Sheet
Executive Summary
Northstar Neuroscience rebuffs takeover attempt: Neuromodulation device developer declines investment fund Tang Capital's unsolicited offer to buy the firm for $2.25 per share as "not in the best interests of all shareholders." Northstar's July 8 response to Tang's July 2 offer notes that the firm will continue to work with investment banker Leerink Swann in considering "strategic alternatives." Northstar stock closed at $1.88 on July 11 (1"The Gray Sheet" July 7, 2008, In Brief)
You may also be interested in...
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Qiagen Buys DxS, Boasts "Deepest" Personalized Medicine Testing Pipeline
Qiagen is boasting the "deepest" pipeline of molecular diagnostics for personalized medicine after acquiring test maker DxS for $95 million, plus up to $35 million in milestone payments
Northstar Goes Supernova: Troubled Brain Stimulation Firm Plans Liquidation
The directors of Northstar Neuroscience, developer of the Renova cortical stimulation system, have elected to liquidate all assets and dissolve the company